You are here

Mixed Results Reported for Arthritis Drug Fostamatinib, Regulatory Filing Scrapped

First STK inhibitor completes phase III program (May 4)

Mixed results have been announced from OSKIRA-2 and OSKIRA-3, the remaining pivotal phase III trials investigating fostamatinib (AstraZeneca), the first oral spleen tyrosine kinase (STK) inhibitor in development as an oral treatment for rheumatoid arthritis (RA).

The OSKIRA-2 study involved patients who had shown an inadequate response to disease-modifying antirheumatic drugs (DMARDs). Fostamatinib in combination with DMARDs showed statistically significant improvements in the number of tender and swollen joints (ACR20 response rates) at 24 weeks in both the 100 mg twice-daily group and the group receiving 100 mg twice daily for 4 weeks followed by 150 mg once daily (39.6% in both arms; P

The OSKIRA-3 study involved patients with an inadequate response to methotrexate (MTX) and a single tumor necrosis factor (TNF)-alpha antagonist. Fostamatinib in combination with MTX showed statistically significant improvements in ACR20 response rates at 24 weeks in the group given 100 mg twice daily (36.2%; P = 0.004) but not in the group given fostamatinib 100 mg twice daily for 4 weeks followed by 150 mg once daily (27.8%; P = 0.168) compared with placebo (21.1%).

The most commonly reported adverse events in the OSKIRA program included hypertension, diarrhea, nausea, headache, and nasopharyngitis.

Based on the totality of the results from the OSKIRA phase III program, including data previously reported from OSKIRA-1, the drug’s developer (AstraZeneca) has decided not to proceed with regulatory filings for fostamatinib.

Source: AstraZeneca; June 4, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug